
|Articles|April 24, 2021
Endocrine Month in Review: April 2021
April's month in review features stories related to new diabetes medications, stem cells, disparities in care of women, and how exposure to endocrine-disrupting chemicals in pregnancy can impact mental health following delivery. Check back in during the last weekend of each month for the next Endocrine Month in Review.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
What Comes Next for Berobenatide? VESPER-3 and Phase 3 Expectations, With John Buse, MD, PhD
4
Berobenatide Monthly Dosing Shows Weight Loss Efficacy in VESPER Trials, With John Buse, MD, PhD
5

























































